v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Grant revenue $ 1,917,491 $ 2,347,250
Operating expenses:    
Research and development 4,837,798 2,814,258
General and administrative 2,382,577 2,127,930
Total operating expenses 7,220,375 4,942,188
Loss from operations (5,302,884) (2,594,938)
Other income (expense):    
Other expense (135) (30)
Interest income 408,985 80,633
Total other income, net 408,850 80,603
Net loss $ (4,894,034) $ (2,514,335)
Per share information:    
Net loss per share of common stock, basic and diluted (in dollars per share) $ (0.56) $ (0.41)
Weighted average shares outstanding, basic and diluted (in shares) 8,702,719 6,170,501
Net unrealized loss on marketable securities $ (34,974) $ 0
Total comprehensive loss $ (4,929,008) $ (2,514,335)